Background of patient-derived xenograft mouse models Since most advanced cancers are still incurable, basic, preclinical and clinical cancer research remains necessary for developing new therapeutic modalities. Many cancer cell lines have been developed, which have for a long time been available for use in basic and preclinical cancer research. However, those cell lines have the disadvantage th...

OBJECTIVES Aggressive cell growth and chemoresistance are notorious obstacles in neuroblastoma therapy. Accumulating evidence suggests that survivin is preferentially expressed in cancer cells and plays a crucial role in cell division and apoptosis dysfunction. Thus, in the present study, we investigated whether silencing of survivin, using a novel small-molecule survivin suppressant, YM155 cou...

Feline mammary tumor is a relatively commonly diagnosed neoplasm in the cat. Development of new veterinary cancer therapies limited by shortage vivo models that reproduce microenvironment and metastatic progression. Four feline orthotopic patient-derived xenograft model (PDX) successfully established NOD-SCID gamma (NSG) mice. The overall success rate PDX establishment was 36% (4/11). Histologi...

Over the past years, a wide variety of in vivo mouse models have been generated in order to unravel the molecular pathology of Chronic Myeloid Leukemia (CML) and to develop and improve therapeutic approaches. These models range from (conditional) transgenic models, knock-in models, and murine bone marrow retroviral transduction models followed by transplantation. With the advancement of immunod...